Last reviewed · How we verify
Capecitabine and Bevacizumab
Capecitabine is a prodrug that converts to fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, while bevacizumab is a monoclonal antibody that blocks VEGF to inhibit tumor angiogenesis.
Capecitabine is a prodrug that converts to fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, while bevacizumab is a monoclonal antibody that blocks VEGF to inhibit tumor angiogenesis. Used for Metastatic colorectal cancer, Metastatic breast cancer, Gastric cancer.
At a glance
| Generic name | Capecitabine and Bevacizumab |
|---|---|
| Also known as | Bevacizumab (Avastin ), Capecitabine (Xeloda) |
| Sponsor | South Eastern European Research Oncology Group |
| Drug class | Fluoropyrimidine antimetabolite + VEGF inhibitor (monoclonal antibody) |
| Target | Thymidylate synthase (capecitabine/5-FU) and VEGF (bevacizumab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Capecitabine is an oral fluoropyrimidine carbamate that is metabolized to 5-fluorouracil (5-FU), which inhibits thymidylate synthase and incorporates into RNA and DNA to impair cancer cell proliferation. Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), preventing new blood vessel formation that tumors depend on for growth and metastasis. The combination leverages chemotherapy-induced cytotoxicity with anti-angiogenic effects.
Approved indications
- Metastatic colorectal cancer
- Metastatic breast cancer
- Gastric cancer
Common side effects
- Hand-foot skin reaction
- Diarrhea
- Nausea
- Fatigue
- Hypertension
- Bleeding
- Thromboembolism
- Proteinuria
Key clinical trials
- Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (PHASE3)
- A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. (PHASE2, PHASE3)
- Pan Tumor Rollover Study (PHASE2)
- A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) (PHASE2)
- Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) (PHASE1)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: